Guggenheim has initiated coverage of Metsera (NASDAQ:MTSR) with a buy rating, citing the company's obesity drug candidates.

Guggenheim has initiated Metsera at buy saying that the biotech's pipeline of injectable and oral nutrient stimulated hormone ...

Guggenheim initiated coverage of Sportradar (SRAD) with a Buy rating and $27 price target Discover the Best Stocks and Maximize Your Portfolio: ...

Wingstop (NASDAQ:WING – Get Free Report) was upgraded by analysts at Guggenheim from a “neutral” rating to a “buy” rating in ...

From sweeping curves to industrial structures, visionary architects have reimagined museums as more than just spaces to view ...

Guggenheim reaffirmed their buy rating on shares of CyberArk Software (NASDAQ:CYBR – Free Report) in a research note issued ...

The performance artist Marina Abramovic celebrated the announcement of a new cultural center in a private home designed by ...

Here is the full schedule for MLB games on FOX this season with key dates and broadcast information: All games will be ...

Investing.com -- Maze Therapeutics Inc (NASDAQ: MAZE ) received bullish coverage from multiple analysts, with Guggenheim, ...

Investing.com -- Wall Street analysts initiated coverage on Metsera with bullish outlook given the biotech firm’s ...

Network Opens Season with Overseas Matchup Featuring Defending World Champion Los Angeles Dodgers and Chicago Cubs FOX Sports ...

Itineraries calling at lesser-visited ports, offering off-the-beaten-track experiences, can help pique clients’ interest in ...